[Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
This case report shows how denosumab apparently treated bisphosphonate-refractory hypercalcaemia caused by a neuroendocrine tumour of the pancreas in a 48-year-old woman. We cannot eliminate the possibility that the patient's DOTATOC-treatment contributed to the decline in plasma calcium concentration. Preliminary results from a recent large, clinical trial, suggest that denosumab is a more potent treatment of malignancy-associated hypercalcaemia than bisphosphonates.